[Study of the resistome of human microbial communities using a targeted panel of antibiotic resistance genes in COVID-19 patients].

Autor:	Yanushevich OO; Russian University of Medicine., Maev IV; Russian University of Medicine., Krikheli NI; Russian University of Medicine., Levchenko OV; Russian University of Medicine., Galeeva JS; Research Institute for Systems Biology and Medicine., Starikova EV; Research Institute for Systems Biology and Medicine., Andreev DN; Russian University of Medicine., Sokolov PS; Russian University of Medicine., Fomenko AK; Russian University of Medicine., Devkota MK; Russian University of Medicine., Andreev NG; Russian University of Medicine., Zaborovsky AV; Russian University of Medicine., Evdokimov VV; Russian University of Medicine., Tsaregorodtsev SV; Russian University of Medicine., Ilina EN; Research Institute for Systems Biology and Medicine., Govorun VM; Research Institute for Systems Biology and Medicine., Bely PA; Russian University of Medicine., Sabelnikova EA; Russian University of Medicine.; Loginov Moscow Clinical Scientific Center., Solodov AA; Russian University of Medicine., Cheremushkin SV; Russian University of Medicine.; Central Clinical Hospital «Russian Railways Medicine»., Shaburov RI; Russian University of Medicine.; Central Clinical Hospital «Russian Railways Medicine»., Kebina AL; Russian University of Medicine.
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2023 Dec 28; Vol. 95 (12), pp. 1103-1111. Date of Electronic Publication: 2023 Dec 28.
DOI:	10.26442/00403660.2023.12.202490
Abstrakt:	Aim: To study overall drug resistance genes (resistome) in the human gut microbiome and the changes in these genes during COVID-19 in-hospital therapy. Materials and Methods: A single-center retrospective cohort study was conducted. Only cases with laboratory-confirmed SARS-CoV-2 RNA using polymerase chain reaction in oro-/nasopharyngeal swab samples were subject to analysis. The patients with a documented history of or current comorbidities of the hepatobiliary system, malignant neoplasms of any localization, systemic and autoimmune diseases, as well as pregnant women were excluded. Feces were collected from all study subjects for subsequent metagenomic sequencing. The final cohort was divided into two groups depending on the disease severity: mild (group 1) and severe (group 2). Within group 2, five subgroups were formed, depending on the use of antibacterial drugs (ABD): group 2A (receiving ABD), group 2AC (receiving ABD before hospitalization), group 2AD (receiving ABD during hospitalization), group 2AE (receiving ABD during and before hospitalization), group 2B (not receiving ABD). Results: The median number of antibiotic resistance (ABR) genes (cumulative at all time points) was significantly higher in the group of patients treated with ABD: 81.0 (95% CI 73.8-84.5) vs. 51.0 (95% CI 31.1-68.4). In the group of patients treated with ABD (2A), the average number of multidrug resistance genes (efflux systems) was significantly higher than in controls (group 2B): 47.0 (95% CI 46.0-51.2) vs. 21.5 (95% CI 7.0-43.9). Patients with severe coronavirus infection tended to have a higher median number of ABR genes but without statistical significance. Patients in the severe COVID-19 group who did not receive ABD before and during hospitalization also had more resistance genes than the patients in the comparison group. Conclusion: This study demonstrated that fewer ABR genes were identified in the group with a milder disease than in the group with a more severe disease associated with more ABR genes, with the following five being the most common: SULI, MSRC, ACRE, EFMA, SAT .
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu